By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology have been published. According to news reporting originating from Memphis, Tennessee, by NewsRx correspondents, research stated, "Prostate cancer is the most common non-cutaneous malignancy in American men. Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance."
Our news editors obtained a quote from the research from the University of Tennessee, "Additionally, docetaxel resistance invariably emerges, leading to disease relapse. Docetaxel resistance is either intrinsic or acquired by adopting various mechanisms that are highly associated with genetic alterations, decreased influx and increased efflux of drugs. Several combination therapies and small P-glycoprotein inhibitors have been proposed to improve the therapeutic potential of docetaxel in prostate cancer. Novel therapeutic strategies that may allow reversal of docetaxel resistance include alterations of enzymes, improving drug uptake and enhancement of apoptosis. In this review, we provide the most current docetaxel reversal approaches utilizing nanotechnology."
According to the news editors, the research concluded: "Nanotechnology mediated docetaxel delivery is superior to existing therapeutic strategies and a more effective method to induce P-glycoprotein inhibition, enhance cellular uptake, maintain sustained drug release, and improve bioavailability."
For more information on this research see: Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resistance Updates, 2014;17(1-2):13-23. Drug Resistance Updates can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Drug Resistance Updates - www.elsevier.com/wps/product/cws_home/623026)
The news editors report that additional information may be obtained by contacting A. Ganju, University of Tennessee, Center Hlth Sci, Dept. of Surg, Memphis, TN 38163, United States. Additional authors for this research include M.M. Yallapu, S. Khan, S.W. Behrman, S.C. Chauhan and M. Jaggi (see also Oncology).
Keywords for this news article include: Antineoplastics, Pharmaceuticals, Drugs, Memphis, Therapy, Genetics, Oncology, Tennessee, Docetaxel, United States, Glycoproteins, Glycoconjugates, Prostate Cancer, Mitotic Inhibitors, Prostatic Neoplasms, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC